<DOC>
	<DOCNO>NCT01206361</DOCNO>
	<brief_summary>The hypothesis difference persistency Xalacom alternative fix dose combination product ( Duotrav Ganfort ) 12 month period .</brief_summary>
	<brief_title>Real World Data Study Assessing The Persistency Of Xalacom And The Other Fixed Dose Combination Products , Duotrav And Ganfort , In The United Kingdom</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Patients receive prescription either Xalacom , Ganfort DuoTrav Greater 18 year old Diagnosed glaucoma ocular hypertension Registered primary care practice &gt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Real world</keyword>
	<keyword>observational</keyword>
	<keyword>retrospective</keyword>
	<keyword>database analysis</keyword>
</DOC>